| Zhang, Ye |
NCT05840341: Clinical Efficacy of QYHJ and Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer |
|
|
| Recruiting | 3 | 306 | RoW | QingyiHuaji optimized formula, standard chemotherapy | Fudan University | Pancreatic Neoplasms | 12/25 | 12/25 | | |
NCT03915132: Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 47 | RoW | Nimotuzumab, Taixinsheng, VMAT | Chinese Academy of Medical Sciences | Nasopharyngeal Carcinoma | 05/20 | 05/22 | | |
NCT05202275: The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs |
|
|
| Recruiting | 2 | 43 | RoW | Olanzapine, Palonosetron, Aprepitant | Chinese Academy of Medical Sciences | Nausea, Vomiting, Head and Neck Squamous Cell Carcinoma, Radiotherapy Side Effect | 12/22 | 09/23 | | |
NCT05375721: Prevention of PONV With Traditional Chinese Medicine |
|
|
| Recruiting | N/A | 300 | RoW | ST36 acupoint injection | The Second Hospital of Anhui Medical University, The First Affiliated Hospital with Nanjing Medical University, Huashan Hospital, Henan Provincial People's Hospital, The Affiliated Hospital of Xuzhou Medical University, First Affiliated Hospital of Jinan University, Beijing Chao Yang Hospital | Postoperative Nausea and Vomiting | 02/24 | 05/24 | | |
NCT06469034: Mixed Reality and Head-mounted Display for Central Venous Catheterization |
|
|
| Recruiting | N/A | 124 | RoW | conventional ultrasound, Mixed reality and head-mounted display ultrasound | The Second Hospital of Anhui Medical University | Central Venous Catheterization | 06/25 | 06/25 | | |
NCT05060068: Effect of Intravenous S-ketamine on Opioid Consumption |
|
|
| Completed | N/A | 345 | RoW | S-ketamine (low dose), LKET, Placebo, CON, S-ketamine (high dose), HKET | The Second Hospital of Anhui Medical University | Breast Cancer Surgery | 07/24 | 07/24 | | |
NCT05607225: Deep Learning-based Classification and Prediction of Radiation Dermatitis in Head and Neck Patients |
|
|
| Recruiting | N/A | 300 | RoW | | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Radiation Dermatitis, Head and Neck Cancer | 06/25 | 06/25 | | |
| Yi, Junlin |
NCT05145660: Optimization of Cervical Nodal CTV for Early and Medium Stage NPC |
|
|
| Recruiting | 3 | 414 | RoW | intensity-modulated radiotherapy (IMRT) with reduced-volume, intensity-modulated radiotherapy, Chemotherapy | Jun-Lin Yi, MD | Nasopharyngeal Carcinoma | 08/27 | 08/27 | | |
NCT03908372: Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2/3 | 120 | RoW | Docetaxel, Taxotere, Cisplatin, DDP, IMRT, intensity-modulated radiotherapy | Chinese Academy of Medical Sciences | Stage II, III, Nasopharyngeal Squamous Cell Carcinoma, Induction Chemotheray, Concurrent Chemoradiotherapy, Reduce Treatment Intensity | 05/21 | 05/25 | | |
NCT03558035: New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 96 | RoW | Induction CT+ CRT group, Concurrent CRT group | Chinese Academy of Medical Sciences | Hypopharyngeal Cancer | 02/21 | 03/21 | | |
LM-HNSCC, NCT05136768: Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 50 | RoW | Sintilimab, Tyvyt®, SBRT, SABR, Platinum based chemotherapy, chemotherapy | Jun-Lin Yi, MD | Head and Neck Squamous Cell Carcinoma, Metastases, Immunotherapy, Stereotactic Body Radiotherapy | 12/23 | 12/24 | | |
NCT06345287: Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC |
|
|
| Recruiting | 2 | 133 | RoW | radical radiotherapy (60Gy), radical radiotherapy (66Gy), radical radiotherapy (70Gy), anti-PD-1 or PD-L1 antibody | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Head and Neck Cancer | 12/25 | 12/26 | | |
NCT04861467: Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 155 | RoW | Camrelizumab | Chinese Academy of Medical Sciences | HNSCC | 07/25 | 12/25 | | |
HN, NCT05777824: Postoperative Management for SCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy |
|
|
| Recruiting | 2 | 84 | RoW | anti-PD-1 or PD-L1 antibody, postoperative radiaotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Head and Neck Cancer | 12/25 | 12/27 | | |
Redbull-1, NCT04949503: A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN |
|
|
| Completed | N/A | 1931 | RoW | nimotuzumab, chemoradiotherapy | Biotech Pharmaceutical Co., Ltd. | Locally Advanced Head and Neck Squamous Cell Carcinoma | 03/23 | 04/23 | | |
